
category:news
Insurers continue to embrace Virtual Healthcare for GLP1s
Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.
category:news
Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.
categeory:watercooler
Novo's CEO goes to congress to testify, but not much is likely to change in the drug's pricing. We dive into some historical context.
drug:am-133
Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it's got any promise.
company:eli-lilly
Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.
category:news
23andMe leaves drug discovery, but embraces providing GLP1 Receptor Agonists -- emphasizing a shift to active preventative care.
drug:amycretin
Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.
category:news
What effects does GLP1 have on ADHD? It's early, but we take a look at some published research.
category:news
Is mimicking more hormones better? Let's find out -- the new GLP1 drug Retatrutide is a *triple* receptor agonist
category:news
Are GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc) primarily brain drugs?
company:eli-lilly
As the race to manufacture more GLP1 medications intensifies, Eli Lilly gets approval in China and more suppliers.
drug:danuglipron
Read more about Dangulipron, Pfizer's GLP1 receptor agonist. Will it be better than Ozempic, Wegovy, Mounjaro, Zepbound and others?
category:news
Teva Pharmaceuticals has started manufacturing a Victoza generic drug (liraglutide), and it's available inside the United States.